Fixed-Duration Glofitamab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed or Refractory Large B-Cell Lymphoma: 3-Year Follow-up from a Pivotal Phase II Study
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-194333
Abstract: Background: Glofitamab is a CD20xCD3 bispecific antibody that engages and redirects T cells to eliminate B cells. In this Phase II study (NCT03075696) of patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL), fixed-duration glofitamab monotherapy… read more here.
Keywords: treatment; duration glofitamab; fixed duration; cell ... See more keywords
Fixed-duration epcoritamab in combination with bendamustine + Rituximab (BR) for first-line (1L) treatment of follicular lymphoma (FL): 3-year results from EPCORE NHL-2 arm 3 demonstrate deep and durable responses with manageable safety
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-5357
Abstract: Introduction: BR is a widely used 1L regimen in FL; however, there remains a need for novel combination therapies that achieve deeper and more durable remissions with manageable safety. Epcoritamab, a CD3×CD20 bispecific antibody, has… read more here.
Keywords: duration; treatment; fixed duration; duration epcoritamab ... See more keywords
Outcomes with a fixed duration combination of bruton tyrosine kinase inhibitors and venetoclax in chronic lymphocytic leukemia: A systematic review and meta-analysis
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-7432
Abstract: Introduction: Single agents, such as Bruton tyrosine kinase (BTK) inhibitors and BCL-2 inhibitors, are being widely used in the treatment of chronic lymphocytic leukemia (CLL), but neither of these is curative. Continuous therapies present a… read more here.
Keywords: duration; combination; fixed duration; btk inhibitors ... See more keywords
Physicians perceptions of fixed-duration epcoritamab + lenalidomide and rituximab regimens in relapsed/refractory follicular lymphoma: Insights from the epcore NHL-2 trial
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-7938
Abstract: Introduction: Follicular lymphoma (FL) is an indolent, yet incurable subtype of non-Hodgkin lymphoma characterized by frequent relapses and risk of transformation to an aggressive disease such as diffuse large B-cell lymphoma. Treatment goals include prolonging… read more here.
Keywords: treatment; trial; fixed duration; lymphoma ... See more keywords
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.
Sign Up to like & getrecommendations! Published in 2022 at "Blood"
DOI: 10.1182/blood.2021014488
Abstract: CAPTIVATE (NCT02910583) is an international phase 2 study in patients aged ≤70 years with previously untreated chronic lymphocytic leukemia (CLL). Results from the cohort investigating fixed-duration treatment with ibrutinib plus venetoclax are reported. Patients received… read more here.
Keywords: ibrutinib plus; treatment; fixed duration; plus venetoclax ... See more keywords
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab
Sign Up to like & getrecommendations! Published in 2022 at "Blood"
DOI: 10.1182/blood.2021015014
Abstract: Kater and colleagues report on 5-year outcomes for patients with relapsed or refractory chronic lymphocytic leukemia (CLL) when treated with fixed-duration venetoclax-rituximab (VenR) in a pivotal randomized trial. Over 50% of patients who completed a… read more here.
Keywords: venetoclax rituximab; relapsed refractory; cll; fixed duration ... See more keywords
Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood.2024024510
Abstract: Key Points • PV with or without rituximab was tested in relapsed/refractory CLL, including after progression during treatment with a covalent BTKi.• These fixed-duration treatments were safe and showed promising efficacy in both covalent BTK-naïve… read more here.
Keywords: relapsed refractory; without rituximab; refractory cll; fixed duration ... See more keywords
Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.20.00131
Abstract: PURPOSE Limited data exist on the optimal duration of immunotherapy, including for non–small-cell lung cancer (NSCLC). We present an exploratory analysis of CheckMate 153, a largely community-based phase IIIb/IV study, to evaluate the impact of… read more here.
Keywords: year fixed; previously treated; duration; continuous versus ... See more keywords
Fixed-duration (FD) first-line treatment (tx) with ibrutinib (I) plus venetoclax (V) for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of the FD cohort of the phase 2 captivate study.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.7501
Abstract: 7501 Background: CAPTIVATE (PCYC-1142) is a multicenter phase 2 study of first-line I+V in CLL. We previously reported results from the Minimal Residual Disease (MRD) cohort wherein undetectable MRD (uMRD) was achieved in over two-thirds… read more here.
Keywords: risk; study; duration; first line ... See more keywords
Prognostic impact of depth of response in Waldenström macroglobulinemia patients treated with fixed duration chemoimmunotherapy.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.8049
Abstract: 8049 Background: The treatment paradigm of Waldenström macroglobulinemia (WM) continues to evolve as new therapies expand our options for this indolent and incurable disease. While more profound responses are generally associated with longer treatment-free intervals,… read more here.
Keywords: therapy; response; major response; impact depth ... See more keywords
Adverse events of interest (AEIs) with zanubrutinib vs fixed-duration combination of venetoclax + obinutuzumab in treatment-naive (TN) chronic lymphocytic leukemia (CLL).
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.e19028
Abstract: e19028 Background: The efficacy and safety of BTKi zanubrutinib (zanu) monotherapy has been evaluated in TN CLL/SLL in SEQUOIA (NCT03336333), while the combination of fixed-duration BCL-2 inhibitor venetoclax + CD20 monoclonal antibody obinutuzumab (VenO) has… read more here.
Keywords: duration; covid; fixed duration; zanu veno ... See more keywords